Actuate Therapeutics Inc (ACTU)
NASDAQ: ACTU
· Real-Time Price · USD
9.14
-0.75 (-7.58%)
At close: May 06, 2025, 3:59 PM
-7.58% (1D)
| Bid | 9.76 |
| Market Cap | 178.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.29M |
| EPS (ttm) | -3.26 |
| PE Ratio (ttm) | -2.8 |
| Forward PE | -5.91 |
| Analyst | Buy |
| Ask | 10.1 |
| Volume | 189,040 |
| Avg. Volume (20D) | 41,806 |
| Open | 10.08 |
| Previous Close | 9.89 |
| Day's Range | 8.07 - 10.28 |
| 52-Week Range | 5.51 - 11.73 |
| Beta | 0.67 |
About ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Ther...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2024
Employees 10
Stock Exchange NASDAQ
Ticker Symbol ACTU
Website https://actuatetherapeutics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ACTU stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 118.88% from the latest price.
Stock Forecasts1 day ago
-6.88%
ACTU stock has given up its prior gain. Actuate Th...
Unlock content with
Pro Subscription
1 day ago
-6.88%
Actuate Therapeutics shares are trading higher after the company announced elraglusib combined with GnP met its primary endpoint in its ongoing Phase 2 trial.